Updated time: 2022-03-24 09:40:16
The technique have been designed and constructed recombinant proteins including an IGFBP3 or a biologically active fragment thereof and an IgG Fc portion linked to the C-terminus of the IGFBP3 or the biologically active fragment thereof. The recombinant proteins including at least one additional domain of other growth factors are also disclosed. Methods for treating tumors, in particular, tumors resistant to the targeted therapy, using the above mentioned recombinant proteins are also provided.
The present recombinant proteins are advantageous in that they not only retain the binding affinity toward the insulin-like growth factor, but also bind with multiple growth factors in the nanomolar range. This multiple targeting effect translates into a more effective cancer therapy that might broaden the therapeutic efficacy and postpone the development of resistance. These recombinant proteins can be administered alone or in combination with existing treatments to treat cancer, while facilitate the design of therapeutic strategies targeting cancer disease in the future.
28A-1040904
TW I723247、US 11,254,722 B2
Cancer Therapy
Elizabeth Wang
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Request for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office

Recombinant proteins and their uses in treating cancer